|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PRDM1 |
Gene summary for PRDM1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PRDM1 | Gene ID | 639 |
| Gene name | PR/SET domain 1 | |
| Gene Alias | BLIMP1 | |
| Cytomap | 6q21 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | O75626 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 639 | PRDM1 | LZE4T | Human | Esophagus | ESCC | 1.55e-06 | 2.66e-01 | 0.0811 |
| 639 | PRDM1 | LZE7T | Human | Esophagus | ESCC | 5.67e-11 | 6.73e-01 | 0.0667 |
| 639 | PRDM1 | LZE6T | Human | Esophagus | ESCC | 3.26e-08 | 6.11e-01 | 0.0845 |
| 639 | PRDM1 | P1T-E | Human | Esophagus | ESCC | 3.87e-04 | 5.77e-01 | 0.0875 |
| 639 | PRDM1 | P4T-E | Human | Esophagus | ESCC | 9.51e-03 | 1.12e-01 | 0.1323 |
| 639 | PRDM1 | P5T-E | Human | Esophagus | ESCC | 2.41e-04 | 1.40e-01 | 0.1327 |
| 639 | PRDM1 | P8T-E | Human | Esophagus | ESCC | 1.11e-03 | 2.60e-01 | 0.0889 |
| 639 | PRDM1 | P10T-E | Human | Esophagus | ESCC | 2.02e-12 | 1.68e-01 | 0.116 |
| 639 | PRDM1 | P15T-E | Human | Esophagus | ESCC | 7.15e-08 | 3.15e-01 | 0.1149 |
| 639 | PRDM1 | P22T-E | Human | Esophagus | ESCC | 1.37e-02 | 7.27e-02 | 0.1236 |
| 639 | PRDM1 | P23T-E | Human | Esophagus | ESCC | 1.42e-19 | 6.32e-01 | 0.108 |
| 639 | PRDM1 | P26T-E | Human | Esophagus | ESCC | 3.38e-18 | 4.29e-01 | 0.1276 |
| 639 | PRDM1 | P28T-E | Human | Esophagus | ESCC | 1.12e-12 | 3.76e-01 | 0.1149 |
| 639 | PRDM1 | P30T-E | Human | Esophagus | ESCC | 2.11e-06 | 3.76e-01 | 0.137 |
| 639 | PRDM1 | P31T-E | Human | Esophagus | ESCC | 1.02e-02 | 9.17e-02 | 0.1251 |
| 639 | PRDM1 | P32T-E | Human | Esophagus | ESCC | 9.87e-04 | 1.82e-01 | 0.1666 |
| 639 | PRDM1 | P36T-E | Human | Esophagus | ESCC | 5.96e-08 | 5.08e-01 | 0.1187 |
| 639 | PRDM1 | P37T-E | Human | Esophagus | ESCC | 8.76e-10 | 3.44e-01 | 0.1371 |
| 639 | PRDM1 | P39T-E | Human | Esophagus | ESCC | 2.93e-13 | 3.71e-01 | 0.0894 |
| 639 | PRDM1 | P42T-E | Human | Esophagus | ESCC | 1.12e-09 | 3.99e-01 | 0.1175 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000170110 | Prostate | BPH | in utero embryonic development | 104/3107 | 367/18723 | 9.17e-09 | 3.10e-07 | 104 |
| GO:000189010 | Prostate | BPH | placenta development | 50/3107 | 144/18723 | 8.97e-08 | 2.20e-06 | 50 |
| GO:00017638 | Prostate | BPH | morphogenesis of a branching structure | 61/3107 | 196/18723 | 3.33e-07 | 7.06e-06 | 61 |
| GO:000189210 | Prostate | BPH | embryonic placenta development | 32/3107 | 82/18723 | 9.93e-07 | 1.80e-05 | 32 |
| GO:190370616 | Prostate | BPH | regulation of hemopoiesis | 97/3107 | 367/18723 | 1.01e-06 | 1.83e-05 | 97 |
| GO:00016557 | Prostate | BPH | urogenital system development | 88/3107 | 338/18723 | 6.05e-06 | 8.83e-05 | 88 |
| GO:00075656 | Prostate | BPH | female pregnancy | 54/3107 | 193/18723 | 4.64e-05 | 4.87e-04 | 54 |
| GO:00097917 | Prostate | BPH | post-embryonic development | 28/3107 | 80/18723 | 4.93e-05 | 5.11e-04 | 28 |
| GO:00607063 | Prostate | BPH | cell differentiation involved in embryonic placenta development | 13/3107 | 25/18723 | 5.04e-05 | 5.21e-04 | 13 |
| GO:00447066 | Prostate | BPH | multi-multicellular organism process | 59/3107 | 220/18723 | 8.01e-05 | 7.66e-04 | 59 |
| GO:00720016 | Prostate | BPH | renal system development | 76/3107 | 302/18723 | 8.55e-05 | 8.09e-04 | 76 |
| GO:00018225 | Prostate | BPH | kidney development | 74/3107 | 293/18723 | 9.31e-05 | 8.76e-04 | 74 |
| GO:19021058 | Prostate | BPH | regulation of leukocyte differentiation | 71/3107 | 279/18723 | 9.94e-05 | 9.21e-04 | 71 |
| GO:0003170 | Prostate | BPH | heart valve development | 23/3107 | 65/18723 | 1.87e-04 | 1.55e-03 | 23 |
| GO:004211010 | Prostate | BPH | T cell activation | 111/3107 | 487/18723 | 2.11e-04 | 1.72e-03 | 111 |
| GO:19031315 | Prostate | BPH | mononuclear cell differentiation | 98/3107 | 426/18723 | 3.43e-04 | 2.55e-03 | 98 |
| GO:0060576 | Prostate | BPH | intestinal epithelial cell development | 8/3107 | 14/18723 | 6.63e-04 | 4.46e-03 | 8 |
| GO:00032813 | Prostate | BPH | ventricular septum development | 23/3107 | 71/18723 | 7.95e-04 | 5.21e-03 | 23 |
| GO:00018935 | Prostate | BPH | maternal placenta development | 14/3107 | 35/18723 | 8.33e-04 | 5.41e-03 | 14 |
| GO:005086310 | Prostate | BPH | regulation of T cell activation | 76/3107 | 329/18723 | 1.32e-03 | 7.95e-03 | 76 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| PRDM1 | IMENT | Colorectum | Healthy | ZC3HAV1,TMCC3,SNX9, etc. | 3.17e-01 |  |
| PRDM1 | AT2L | Lung | AIS | ANKRD28,MZB1,TXNDC5, etc. | 6.50e-01 |  |
| PRDM1 | PLA | Thyroid | HT | RNF213,ETS1,CD2, etc. | 5.77e-01 |  |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PRDM1 | SNV | Missense_Mutation | c.641N>C | p.Gly214Ala | p.G214A | O75626 | protein_coding | tolerated(0.05) | benign(0.003) | TCGA-A7-A0DA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| PRDM1 | SNV | Missense_Mutation | c.1741G>A | p.Ala581Thr | p.A581T | O75626 | protein_coding | tolerated(0.4) | benign(0.007) | TCGA-A8-A06R-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | CR | |
| PRDM1 | SNV | Missense_Mutation | c.1629C>A | p.Ser543Arg | p.S543R | O75626 | protein_coding | tolerated(0.4) | benign(0.034) | TCGA-A8-A09N-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| PRDM1 | SNV | Missense_Mutation | c.709G>A | p.Glu237Lys | p.E237K | O75626 | protein_coding | tolerated(0.52) | benign(0.009) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| PRDM1 | SNV | Missense_Mutation | c.1735N>A | p.Val579Ile | p.V579I | O75626 | protein_coding | tolerated(0.33) | benign(0.023) | TCGA-AC-A6IW-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| PRDM1 | SNV | Missense_Mutation | novel | c.1288N>C | p.Ser430Arg | p.S430R | O75626 | protein_coding | deleterious(0.05) | benign(0.013) | TCGA-AN-A04D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| PRDM1 | SNV | Missense_Mutation | c.1047C>G | p.Ser349Arg | p.S349R | O75626 | protein_coding | tolerated(0.2) | benign(0.409) | TCGA-AN-A0AT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| PRDM1 | SNV | Missense_Mutation | c.461A>G | p.Glu154Gly | p.E154G | O75626 | protein_coding | deleterious(0.02) | possibly_damaging(0.502) | TCGA-B6-A0I9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | |
| PRDM1 | SNV | Missense_Mutation | rs764666878 | c.2298N>C | p.Glu766Asp | p.E766D | O75626 | protein_coding | deleterious(0.04) | probably_damaging(0.96) | TCGA-BH-A42U-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| PRDM1 | SNV | Missense_Mutation | c.1850N>G | p.His617Arg | p.H617R | O75626 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-D8-A1JP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |